Close Menu

People in the News

May 19, 2020

Sema4: Martin Chavez

Sema4 has appointed Martin Chavez to its board of directors. Chavez served in several senior roles at the investment bank Goldman Sachs, including chief information officer, CFO, and global cohead of the firm's securities division. He was also a member of the firm's management committee.

Chavez cofounded Kiodex and Quorum Software Systems, which provide software for the finance and oil and gas industries, respectively.In addition to Sema4, Chavez serves on the boards of Paige, an AI biomedical tech startup, and Recursion, a software-based drug discovery company. This month he was named president of the Harvard Board of Overseers and serves on the Stanford Medicine board of fellows and the Institute for Advanced Study's board of trustees.

Chavez holds a master's degree in computer science from Harvard and a doctorate in Medical Information Sciences from Stanford University.

May 15, 2020

Centogene: Sun Kim, Oved Amitay

Sun Kim will become interim chief business officer of Centogene, effective June 1. He will replace Oved Amitay, who will leave the company on May 31, until a permanent chief business officer has been appointed. Kim is currently Centogene's chief strategy and investor relations officer. Prior to that, he was head of corporate strategy at Shire, and before that, he held multiple roles in the Alcon division of Novartis. Kim holds PhD and MS degrees in chemical engineering from Stanford University.

May 12, 2020

Alveo Technologies: Bharat Tewarie

Alveo Technologies has appointed Bharat Tewarie to its board of directors. Tewarie recently founded Boston BioPharma Consultants and was formerly executive vice president and chief marketing officer at biopharma firm UCB. He currently is on the board of Ahara Biosciences and Duluth Medical Technologies. Alameda, California-based Alveo is developing an at-home diagnostic platform called be.well that leverages nucleic acid amplification for the molecular detection of infectious diseases.

May 11, 2020

Roche: Fritz Gerber

Roche announced that former Group CEO and Chairman of the Board Fritz Gerber died at 92. Gerber served as group CEO from 1978 to 1998 and decentralized the company's structures. Under his leadership, Roche acquired a majority stake in Genentech, took over Boehringer Mannheim, and acquired PCR technology. After retiring as chairman in 2001, he remained an honorary chairman throughout the rest of his life. 

Gerber was also on the board of IBM and created the Fritz Gerber Foundation for Gifted Young People.

May 06, 2020

Centogene: Angelos Baxevanis

Angelos Baxevanis has joined Centogene as senior vice president of communication and marketing. He joins the company from AAB Consulting, where he worked with Sobi Pharmaceuticals on enhancing commercial capabilities for rare disease. Prior to that, he led marketing communication and excellence at Smith & Nephew, and before that, he held several positions at Astra Zeneca. Baxevanis has an MBA from the Alba Graduate Business School and a master's degree in chemical engineering from the University of Patras in Greece.

May 06, 2020

OraSure Technologies: Lisa Nibauer

OraSure Technologies has appointed Lisa Nibauer as executive vice president and business unit leader for infectious disease. She will replace Tony Zezzo, who has announced that he will retire from the company. Zezzo's official retirement date will be mutually determined, and he will maintain his current role in OraSure's COVID-19 activities while he coordinates the transition with Nibauer, who will join the company on May 11. Nibauer most recently served as vice president and general manager of global medication delivery solutions at Becton Dickinson.

May 06, 2020

First Light Diagnostics: Joanne Spadoro

First Light Diagnostics announced that Joanne Spadoro is the company's COO. Last September she joined the company as VP of R&D and regulatory affairs. Previously, Spadoro was senior VP of product development and operations at Roche Molecular Systems, leading the teams that launched PCR-based products globally for infectious disease diagnostics, viral load monitoring, and blood screening applications. 

She also served as CSO and worldwide VP of operations at Immucor, developing the company's molecular immunohematology test for the detection of extended blood antigens. Spadoro was also previously the COO at T2 Biosystems. 

May 05, 2020

Grail: Mostafa Ronaghi

Mostafa Ronaghi has joined Grail's board of directors. Ronaghi is currently Illumina's senior vice president of entrepreneurial development, and previously served as the company's senior VP and chief technology officer, a role in which he led internal research and technology and cofounded Grail. He also cofounded the Illumina Accelerator.

In 2007, Ronaghi cofounded Avantome, a privately held sequencing company that was acquired by Illumina in 2008. Before this, he cofounded NextBio, a search engine for life science data that was acquired by Illumina in 2013. In 2001, Ronaghi cofounded ParAllele Bioscience, which was eventually acquired by Affymetrix, and was involved in the development and commercialization of highly multiplexed technology for genetic testing. In 1997 he cofounded Pyrosequencing AB, which was renamed Biotage in 2003. Ronaghi earned his PhD from the Royal Institute of Technology in Sweden and was a principal investigator at Stanford University from 2002 until 2008, focused on the development of novel tools for molecular diagnostic applications. He also serves on the board of directors of BaseHealth and Clear Labs. 

May 04, 2020

Oncimmune: Richard Sharp

Oncimmune Holdings announced Richard Sharp has stepped down as a non-executive director of the firm, effective May 4, in order to focus on his new role as senior strategic adviser to the UK government in connection with the coronavirus pandemic. Sharp remains a shareholder in Oncimmune.

Apr 29, 2020

Transplant Genomics: Peter Meintjes

Eurofins-Transplant Genomics has appointed Peter Meintjes as chief commercial officer to lead the commercialization of the company's TruGraf blood test for kidney transplant surveillance. Meintjes joins TGI after six years at Omixon, where most recently served as CEO after having also held the roles of chief commercial officer and director of US operations. Meintjes also previously worked as VP of business development for Biomatters.

Apr 29, 2020

Grail: Satnam Alag

Grail has appointed Satnam Alag as senior VP of software engineering. Prior to Grail, Alag most recently served as VP of software engineering, product development at Illumina. Before Illumina, Alag was chief technology officer at NextBio, which was acquired by Illumina in 2013. Alag has also held other senior software architecture positions, including chief software architect at Deem.  

Apr 24, 2020

HTG Molecular Diagnostics: Maureen Cronin

Maureen Cronin has resigned as CSO and senior VP at HTG Molecular Diagnostics, effective April 30. She will resume her consulting practice to pursue other interests, the company said. Cronin joined HTG Molecular in November 2018 after serving as executive director of strategic information management for Celgene from 2012 to 2017. Before that, she was senior VP of research and product development for Foundation Medicine. She also served as VP of translational research and senior director of technology development at Genomic Health.

Apr 21, 2020

Sense Biodetection: John Bishop

Sense Biodetection appointed John Bishop as a non-executive director.

Bishop, Cepheid's CEO from 2002 until its acquisition by Danaher in 2016, will play a pivotal strategic role at Sense as the company rapidly scales up production and distribution of its first products, including its COVID-19 test, Veros SARS-CoV-2.

At Cepheid, Bishop was instrumental in accelerating the firm's growth as a molecular diagnostics company. He oversaw the successful launch and commercialization of its GeneXpert and GeneXpert Xpress systems.

Apr 21, 2020

Truvian Sciences: Jean-Pierre Millon

Truvian Sciences appointed Jean-Pierre Millon to its board of directors. He is currently also a board member at CVS Health and was president and CEO of PCS. He previously held leadership positions at Eli Lilly and is a cofounder of consuting and investing firm BLS. 

Apr 21, 2020

Personal Genome Diagnostics: Megan Bailey, CEO

Personal Genome Diagnostics has appointed Megan Bailey as its new CEO, succeeding Douglas Ward who served as the firm's CEO from 2016. Bailey initially joined PGDx as VP of marketing and was then promoted to chief commercial officer, leading the company’s marketing, sales, customer support, and communications arms in developing and executing global go-to-market strategies. She contributed to the achievement of CE marks for both the elio tissue complete assay and elio plasma resolve products and played a key role in establishing strategic collaborations with organizations such as the Mayo Clinic and PathGroup.
 
Before joining PGDx, Bailey spent more than 14 years at Roche, most recently as that firm's senior director of commercial operations. Prior to that, she held various marketing leadership roles for Roche's tissue diagnostics division.
Apr 20, 2020

ACMG Foundation: Aleksandar Rajkovic

Aleksandar Rajkovic has been elected to the board of directors of the ACMG Foundation for Genetic and Genomic Medicine, a nonprofit foundation dedicated to facilitating the integration of genetics and genomics into medical practice. Rajkovic is a professor of pathology and obstetrics/gynecology and reproductive sciences at the University of California, San Francisco. He is the UCSF chief genomics officer and medical director and chief of the Center for Genetic and Genomic Medicine that organizes, coordinates and oversees clinical genetics and genomics services across the entire UCSF Health system. He also serves as the director of the Genomic Medicine Initiative there. Rajkovic has an MD/PhD in medicine and molecular biology from Case Western Reserve University.

Apr 20, 2020

Mesa Biotech: Ingo Chakravarty

Mesa Biotech has appointed Ingo Chakravarty as the firm's president and CEO, effective April 15. Chakravarty replaces Hong Cai, a cofounder of Mesa, who has transitioned to be the firm's chief technology officer. Chakravarty most recently served as president and CEO of Navican Genomics, and has held senior leadership positions at GenMark Diagnostics, Gen-Probe, Roche, and Ventana Medical Systems.

Apr 17, 2020

Todos Medical: Lauren Chung

Todos Medical has appointed Lauren Chung to its board of directors. Chung is the founder and CEO of Minleigh, a firm focused on identifying, evaluating, and partnering with companies for investments and strategic, operational, and commercial opportunities.

She has more than 20 years of healthcare investment management, investment banking, and advisory experience and is currently a venture partner at South Korea-based Yozma Group Asia.

Chung was previously a managing director at WestPark Capital and a cofounder of Tokum Capital Management, a global healthcare fund. She managed healthcare investment portfolios at RBR Capital, Kingdon Capital, and Pequot Capital. Earlier, Chung was a research scientist working in neurodegenerative and genetic disorders at Massachusetts General Hospital and Boston Children's Hospital.

Apr 16, 2020

SphingoTec: Achim Plum

SphingoTec has appointed Achim Plum its managing director and chief commercial officer. He had been a business advisor to SphingoTec since May 2019. Before that, he was an exective board member and chief business officer at Curetis, which recently merged with OpGen. Prior to that, he held senior management positions at Siemens Healthcare and at Epigenomics.

Apr 16, 2020

Inflammatix: João Fonseca

Inflammatix has appointed João Fonseca as chief technology officer to oversee its molecular assay development and engineering teams as the firm advances its rapid tests for acute infections, sepsis, and COVID-19 risk stratification.

Since 2006, Fonseca has served as founder, CEO, and chief scientific officer of Biosurfit, a Lisbon, Portugal-based company whose blood tests diagnose multiple conditions at the point of care. The company's tests are broadly available throughout Europe.

Prior to Biosurfit, Fonseca was a professor in physics and experimental physics at the Technical University of Lisbon and a researcher at the University of Lisbon. He also founded a non-profit organization that works with patients and researchers to advance novel cancer treatments and research.

Apr 14, 2020

Caris Life Sciences: Chadi Nabhan

Caris Life Sciences has appointed Chadi Nabhan as chairman of its Precision Oncology Alliance, a collaborative network of 36 academic, hospital, and community-based cancer institutions focused on precision medicine. Nabhan was previously chief medical officer of Aptitude Health. Prior to that he was CMO at Cardinal Health Specialty Solutions. Nabhan was also an associate professor of medicine and medical director of the Clinical Cancer Center at the University of Chicago. He is currently an adjunct professor in the Department of Clinical Pharmacy at the University of South Carolina.

Apr 10, 2020

Genetron Health: Yun-Fu Hu

Chinese precision oncology company Genetron Holdings (Genetron Health) has appointed Yun-Fu Hu as chief medical officer. A former deputy director with the US Food and Drug Administration, Hu will be tasked to guide the company in its in vitro diagnostic device registration and regulatory affairs as well as its biopharma services business. At the FDA Hu led a team in premarket reviews and post-market compliance of IVD products and laboratory-developed tests for genetic testing, molecular cancer diagnostics, companion diagnostics, radiodosimetry, digital pathology, and artificial intelligence devices. Prior to joining FDA, Hu had more than 10 years of product development experience in the diagnostic and pharmaceutical industries.

Apr 10, 2020

Adaptive Biotechnologies: Mark Adams, Jyoti Palaniappan, Thomas Snyder

Adaptive Biotechnologies has appointed Mark Adams as chief technical officer, Jyoti Palaniappan as senior vice president of clinical diagnostics for the ImmunoSeq Dx program, and Thomas Snyder as vice president of research, ImmunoSeq Dx.

Adams has been involved in the strategy, design, and implementation of large-scale bioinformatics and data analytics programs for companies including SVB Leerink, Celmatix, Good Start Genetics, and Variagenics. He holds a PhD in cell biology from Baylor College of Medicine and completed his postdoc in computational biology at Boston University. He assumes the CTO role from Sean Nolan, who will fill a newly created role of distinguished engineer.

Palaniappan previously served as chief commercial officer for Bigfoot Biomedical. He also spent 11 years in Abbott's diabetes care business. Prior to Abbott he led global and US commercial organizations for Thermo Fisher Scientific, and provided strategic consulting services at McKinsey & Company. He holds an MBA/MPH from Emory University.

Snyder returns to Adaptive after five years as head of computational biology at Verily (formerly Google Life Sciences).

Apr 10, 2020

Grail: Harpal Kumar

Grail has appointed Harpal Kumar as president of Grail Europe, a new role within the company. Kumar joins Grail from Johnson & Johnson where he most recently served as senior vice president and head of innovation EMEA, overseeing a portfolio of regional co-investments and collaborations. Before joining Johnson & Johnson, Kumar spent 15 years with Cancer Research UK, serving as the organization's CEO from April 2007 until June 2018. Prior to this, he was CRUK's COO and executive director of development, as well as chief executive of CRUK subsidiary Cancer Research Technology.

Before CRUK, he worked with McKinsey & Co, the Papworth Trust, and Nexan Group. He received a master's degree in chemical engineering from the University of Cambridge, and an MBA from Harvard Business School. He has been awarded honorary doctorates from the Universities of Manchester, Newcastle, and Glasgow, and the Institute of Cancer Research, and he is a Fellow of the Academy of Medical Sciences. In 2016, he was knighted by Her Majesty Queen Elizabeth II for services to cancer research.

Apr 08, 2020

OraSure: David Shulkin

Former Secretary of the US Department of Veterans Affairs David Shulkin has been appointed to the board of OraSure Technologies, the firm said. He will also serve on the board's audit committee, and nominating and corporate governance committee. Shulkin is currently president and CEO of Shulkin Solutions and previously was chief executive at hospitals and health systems including Beth Israel in New York and Morristown Medical center in New Jersey.  

Pages